News

A human monoclonal antibody, BAT2206 is currently undergoing regulatory review with several health authorities, including the China National Medical Products Administration (NMPA), the US Food and Drug Administration

BAL2420 is a lipooligosaccharide phosphoethanolamine transferase A (LptA) inhibitor, a new class of antibiotics with bactericidal activity against Gram-negative bacteria, including drug-resistant strains. The additional CARB-X funding is

The collaboration focuses on a three-asset portfolio of preclinical next-wave ADCs. These ADC assets were developed through a joint effort between WuXi Biologics and Hangzhou DAC Biotechnology, leveraging

With this investment, Gilead’s equity ownership in Assembly Bio has increased to 29.9%. These funds are expected to extend Assembly Bio’s cash runway to mid-2026 and will support

This follows orphan drug status granted by the US Food and Drug Administration (FDA) in November 2020. Currently, mitapivat is approved in the US under the brand name

The investment will specifically support the development of NG-350A through a Phase Ib clinical proof-of-concept study, FORTRESS which will assess the clinical complete response rates of the therapy

Under the agreement terms, EpimAb is set to receive an upfront payment, along with development and sales milestones that could exceed $1bn, provided multiple drug candidates reach commercialisation.

The designation is supported by the positive outcomes from the double-blind Phase III HERCULES trial, where the therapy showed a 31% delay in the time to onset of

This initiative is facilitated through a Named Patient Program (NPP), allowing patients to access these treatments based on clinical evidence and medical needs prior to regulatory approval. The